

Special Issue

Thymic Tumors: New Developments and Future Directions in Molecularly Informed Therapies

Message from the Guest Editors

Thymomas (TM) and thymic carcinomas (TC) are among the adult tumors with the lowest mutational burden, and the oncogenic drivers behind these neoplasms are currently unknown. After more than a decade of molecularly informed therapies, patients with thymomas (TM) and thymic carcinomas (TC) have experienced limited benefits from the latest developments, and the optimal therapy for these tumors remains to be defined. The tumor heterogeneity and profound biological differences between TM and TC necessitate subtype-specific tailored approaches. Due to the rarity of TM and TC, only a few prospective clinical trials have been conducted, often with disappointing results. It is thus of crucial importance that future clinical trials use the best current evidence and all available information. In this Special Issue, experts in the field will review the status quo of basic research and of the medical treatment of TM and TC, and will suggest directions for future research and informed clinical trials.

Guest Editors

Prof. Dr. Philipp Ströbel

Institute of Pathology, University Medical Center Göttingen, Göttingen, Germany

Prof. Dr. Alexander Marx

Institute of Pathology, University Medical Center Göttingen, Göttingen, Germany

Deadline for manuscript submissions

closed (1 December 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/161458

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)